Clinical Trial

A Phase Ib Study of GC101 in NSCLC

Study acronym: MIZAR-005
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
20 participants are expected to be enrolled for the Phase Ib clinical trial，this trail is expected to be finished in 36 months.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-01-01 -> 2027-01-01 2026-08-06
minor Completion pushed: 2027-07-01 -> 2028-07-01 2026-08-06
Trial Details
NCT Number NCT06473961
Lead Sponsor Shanghai Juncell Therapeutics
Conditions Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
Enrollment 20 participants
Start Date 2024-10-14
Primary Completion 2027-01-01 (estimated)
Study Completion 2028-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-05